Nxera Pharma Co., Ltd. provides an update on operational activities and reports fourth-quarter and full-year results for 2025. The full report can be viewed on their website. The company’s President and CEO, Christopher Cargill, highlights strategic progress and commercial growth in Japan and the APAC region. Key achievements include milestone payments and progress in late- and commercial-stage portfolio expansion.

Operational highlights for Q4 2025 include continued growth in sales of PIVLAZ® in Japan, with a market share increase to 74%. Net sales for PIVLAZ® in Q4 were JPY 4,545 million. Approval was obtained for a partial change to the QUVIVIQ™ manufacturing and marketing authorization, with FY 2025 net sales of JPY 4,327 million.

Nxera’s partner, Cancer Research UK, presented positive data from a Phase 1 trial of HTL’732 at the ESMO Congress 2025. The trial demonstrated target engagement and early efficacy in two tumor types. The company also focused on restructuring to enhance profitability and regained full rights to the GPR52 agonist program for schizophrenia.

Post-period events include licensing rights to vamorolone for Duchenne Muscular Dystrophy and a milestone payment from Centessa Pharmaceuticals. Positive results were reported from a Phase 3 trial of daridorexant in South Korea, with plans for a marketing authorization application.

Financial highlights for the 12-month period ended December 31, 2025, show a total revenue of JPY 29,615 million. R&D expenses increased to JPY 14,466 million, while SG&A expenses decreased to JPY 15,225 million. The operating loss was JPY 8,462 million, with a net loss of JPY 12,530 million. Cash and cash equivalents totaled JPY 20,365 million at the end of the year.

Read more at GlobeNewswire: Nxera Pharma Operational Highlights and Consolidated